The widespread success of NeuroPerformance among seniors leads AUUM to explore its potential benefits for "super-agers."

With COVID-related restrictions relaxed, AUUM researchers and leadership reconnect with clients and discover numerous testimonials of improvement in visual performance, particularly in clients over 60. Results from high performance athletes across many sports continue to demonstrate consistent and rapid improvements.

AUUM perseveres through the COVID-19 pandemic to develop scale-up methodologies and produce raw Inuit oil from the community seal hunt. A successful Inuit harvest enables the primary processing and production of finished raw oil for future AUUM products.

AUUM collaborates with Inuit hamlets and hunters to develop harvest and collection techniques for raw blubber. This raw material is then shipped south to AUUM labs for further analysis and testing.

Preliminary results of a McGill University/Canadian Cancer Society double-blind study in chemotherapy-induced peripheral neuropathy are very encouraging. This research uses specifically AUUM-produced products.

AUUM mammalian omega-3 results on Diabetic Peripheral Neuropathy presented at International Neurology congresses in Toronto, South Africa, and Europe. Published in Canadian Journal of Diabetes Oct 2016, these finding show that 12 months of using specified AUUM mammalian omega oil supplements can stop the progression of DPN.

AUUM was the product sponsored for a Canadian Cancer Society funded double-blind clinical trial studying chemotherapy-induced peripheral neuropathy. This trial is being conducted by researchers at the McGill University Health Centre - Segal Cancer Centre.

AUUM was the product sponsored of the first clinical trial to investigate the therapeutic use of omega-3s to stop the progression of nerve damage in Diabetic Neuropathy. The trial, funded by the Canadian Diabetes Association is being conducted by researchers at the University of Toronto - Department of Nutritional Sciences, Toronto General Hospital - Division of Neurology and the Mt. Sinai Hospital - Leadership Centre for Diabetes. Study findings reported on the effect of AUUM omega-3s on changes in nerve structure and nerve function. The results were presented at the 14th International Congress on Neuromuscular Disease, in Toronto, Canada.

Researchers at the University of Toronto, Department of Nutritional Science used AUUM Sublingual-D in a clinical trial investigating the effect of omega-3 supplementation on nerve function and exercise performance. Findings showed 21 days of AUUM Sublingual-D increased muscle activation 9% and reduced sprint cycling fatigue 5% compared to placebo.

Building on the success of AUUM Sublingual-D, AUUM D3A was developed to allow for sublingual delivery of vitamin A, D and omega-3s. Both products were used to support the work of the Balanced Heart Mission and its studies with autistic children. The overwhelming feedback from this work was that supplementation with AUUM Sublingual-D or D3A improved speech and behaviour.

Continued R&D by AUUM enabled the development of Sublingual-D, the first omega-3 product designed for sublingual delivery of omega-3s.

Internal and external research revealed that seal oil omega-3s were a superior source of omega-3s because of their unique structure and higher digestibility compared to fish oil. AUUM started to produce and market mammalian Omega-3 capsules.

AUUM Inc. was a manufacturer of hemp-based Omega-3 skin care products and began R&D with seal oil to add long-chain anti-inflammatory Omega-3s into products.